Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP6981 in Patients With Schizophrenia
NCT03356639Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP6981 in schizophrenia (4 arms), sponsored by Astellas Pharma. Primary endpoints: Nature, frequency and severity of adverse events up to 65 days, Cogstate general composite score of executive function and memory at Day 14 and 9 more. Started Jan 2018; status: completed.
02
Drugs
ASP6981
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03356639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356639.